UBS Downgrades Pfizer to Neutral, Lowers Price Target to $47

UBS analyst Colin Bristow downgrades Pfizer (NYSE:PFE) from Buy to Neutral and lowers the price target from $55 to $47.

UBS analyst Colin Bristow downgrades Pfizer (NYSE:PFE) from Buy to Neutral and lowers the price target from $55 to $47.

Total
0
Shares
Related Posts